ATNM
ATNM clinical trials: Actinium Pharmaceuticals, Inc.
Every trial on ClinicalTrials.gov where Actinium Pharmaceuticals, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 9
- Trials linked
- 6
- As lead sponsor
- 3
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ATNM on the catalyst calendar · ATNM registry changes
- Primary completion Feb 2029Sponsor estimatePhase 2/Phase 3NCT07157514Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AMLActinium Pharmaceuticals · Acute LeukemiaNot yet recruitingATNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2023Sponsor estimatePhase 1/Phase 2NCT03867682Venetoclax and Lintuzumab-Ac225 in AML PatientsActinium Pharmaceuticals · Acute Myeloid LeukemiaUnknown statusATNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2023Sponsor estimatePhase 1/Phase 2NCT03932318Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML PatientsActinium Pharmaceuticals · Acute Myeloid LeukemiaWithdrawnATNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2022ActualPhase 3NCT02665065Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid LeukemiaActinium Pharmaceuticals · Acute Myeloid LeukemiaActive, not recruitingATNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2018ActualPhase 1/Phase 2NCT02575963Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) PatientsActinium Pharmaceuticals · AMLCompletedATNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2020ActualPhase 1NCT02998047A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple MyelomaActinium Pharmaceuticals · Refractory Multiple MyelomaTerminatedATNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 12, 2030Sponsor estimatePhase 1NCT07015684131I-apamistamab-based Conditioning for Hematopoietic Stem Cell Transplant (HSCT) in Advanced Sickle Cell Disease (SCD)Columbia University · Sickling Disorder Due to Hemoglobin SRecruitingATNMCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2029Sponsor estimatePhase 1/Phase 2NCT06768905IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCLUniversity of Texas Southwestern Medical Center · Non Hodgkin LymphomaRecruitingATNMCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2015ActualPhase 1NCT00672165Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid...Memorial Sloan Kettering Cancer Center · LeukemiaCompletedATNMCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner